Coverage
AstraZeneca PLC said its experimental drug baxdrostat significantly lowered blood pressure in patients with a hard-to-treat form of hypertension, meeting the main goal of a late-stage trial.
AstraZeneca PLC and Daiichi Sankyo said their drug Datroway significantly improved survival for patients with an aggressive form of breast cancer in a late-stage study.
AstraZeneca PLC said its cancer drug Enhertu, developed with Daiichi Sankyo, showed a significant improvement over the standard treatment in a late-stage trial for patients with a high-risk form of early breast cancer.
AstraZeneca PLC on Monday announced plans to directly list its ordinary shares on the New York Stock Exchange, a move aimed at attracting a broader base of global investors and accessing deeper capital pools.
AstraZeneca PLC said its drug Koselugo won a key European regulatory backing for use in adults, a positive development for the company following recent setbacks in its drug pipeline.
AstraZeneca PLC said its drug Tezspire, developed with Amgen Inc., won a key European regulatory backing for a new use, a positive development for the company following recent trial setbacks.
Filings
| Filing | Date |
|---|---|
| Total Voting Rights | 1 Jul 2025 |
| Datroway approved in US for EGFRm lung cancer | 24 Jun 2025 |
| AstraZeneca enters into collaboration with CSPC | 13 Jun 2025 |
| Director/PDMR Shareholding | 12 Jun 2025 |
| Fixed-duration Calquence approved in EU for 1L CLL | 6 Jun 2025 |
| Total Voting Rights | 2 Jun 2025 |
| Block listing Interim Review | 2 Jun 2025 |
| Imfinzi recommended in EU for bladder cancer | 27 May 2025 |
| Director/PDMR Shareholding | 23 May 2025 |
| Director Declaration | 21 May 2025 |
| Acquisition of EsoBiotec completed | 20 May 2025 |
| Imfinzi improved DFS in early bladder cancer | 9 May 2025 |